Trial Profile

First-in-human Phase 1/2 Trial of EGL-001 in Adult Patients with Selected Advanced And/or Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 06 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EGL 001 (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man
Sponsors Egle Therapeutics

Most Recent Events

17 Mar 2025 According to an Egle Therapeutics media release, company received funding from the French government through France 2030, the funding granted under the 'Innovations in Biotherapies and Bioproduction' call for projects will enable company to accelerate the development of EGL-001, which is currently being evaluated in a Phase I/II clinical trial in France and Spain.
07 Oct 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com